Lomb

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Retrieved on: 
Wednesday, December 20, 2023
ERNA, Buffalo, Partnership, Messenger, Bristol Myers Squibb, Strategic planning, Novartis, GE HealthCare, Bausch, Cancer, Patient, State university system, Lomb, Management

CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA ) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA ) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024.
  • Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer.
  • Sanjeev has an impressive track record in leadership, strategic planning, and business development across various global organizations in the pharmaceutical and healthcare sectors.
  • At Cornerstone, he also held the roles of Chief Operations Officer and Chief Business Officer.

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
CNS, Acquisition, Mydriasis, Audit committee, Telecanthus, Visual acuity, CFO, Headache, Net, Patient, Presbyopia, Research, Element, Tropicamide, Lomb, Growth, Inflammation, Vomiting, Intraocular pressure, ACE, ADT Inc., American Academy, Abnormal psychology, New Drug Application, Nausea, Tachycardia, Mouth, Hypersensitivity, NDA, Allied health professions, International Joint Commission, Photophobia, Psychotic Reaction, Cholinergic, Pilocarpine, Pallor, Reader's Digest, Blood pressure, Bausch, Carbachol, Near-sightedness, Allergy, FDA, Contact, Central nervous system, PDUFA, Hypertonia, Pharmaceutical industry, Management, Nursing, Telescopic sight, Video game, Euronext, Ophthalmology

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, topical ophthalmic company leveraging its Optejet® dispensing technology for both internally developed and acquired programs as well as out-licensing for additional indications, today announced its financial and operating results for the third quarter ended September 30, 2023.

Key Points: 
  • Advanced its Gen-2 Optejet device and anticipates shipping to MicroPine partners Bausch and Lomb and Arctic Vision by year-end 2023.
  • Research and development expenses totaled approximately $3.6 million for the third quarter of 2023 as compared to $3.9 million for the third quarter of 2022.
  • For the third quarter of 2023, general and administrative expenses were approximately $2.9 million, compared to $3.4 million for the third quarter of 2022.
  • Total operating expenses for the third quarter of 2023 were approximately $6.5 million compared to $7.2 million for the third quarter of 2022.

Prominent Casana Executives Named to Prestigious American Heart Association Boards

Retrieved on: 
Monday, August 28, 2023
RIT, DNA, American Heart Association, Stroke, Bausch, AHA, Interdisciplinarity, Cepheid variable, Faculty, Microsystem, Lomb, Software, Pharmaceutical industry

ROCHESTER, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Today, Casana , the industry leader in monitoring heart health through smart toilet seats, is thrilled to announce the appointment of two esteemed executives to the boards of the American Heart Association (AHA).

Key Points: 
  • ROCHESTER, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Today, Casana , the industry leader in monitoring heart health through smart toilet seats, is thrilled to announce the appointment of two esteemed executives to the boards of the American Heart Association (AHA).
  • Both executives have been selected to contribute their expertise to the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke.
  • Both Lew and Borkholder bring a wealth of experience and a passion for cardiovascular health and business strategy to their roles on the American Heart Association boards.
  • "We are immensely proud of both appointments to the American Heart Association boards.

Visiox Pharma Expands Executive Team with the Appointment of Sanjay Malieckal as Vice President of Sales and Marketing

Retrieved on: 
Wednesday, July 5, 2023
Union of Sales and Marketing Professionals, Bausch, Sanjay, Marketing, Patient, Lomb, Pharmaceutical industry

"Sanjay's appointment marks a significant milestone achievement for Visiox," said Ryan Bleeks, Chief Executive Officer.

Key Points: 
  • "Sanjay's appointment marks a significant milestone achievement for Visiox," said Ryan Bleeks, Chief Executive Officer.
  • "His proven commercial experience in building teams and launching products is critical as we realize the potential of the expected commercialization of our portfolio."
  • "I am thrilled to join the Visiox team where we will focus on advancing treatments for patients and eyecare providers.
  • My goal is to build a strong commercial culture and capabilities that will drive successful launches in the near term," stated Sanjay Malieckal.

Joseph C. Papa Joins Water Street Healthcare Partners

Retrieved on: 
Wednesday, June 14, 2023
Water Street District (Henderson, Nevada), Cardinal Health, Water, Growth, Novartis, Lomb, Water Street, Investment, Arthritis, Pharmaceutical industry, Bausch, Celecoxib

CHICAGO, June 14, 2023 /PRNewswire/ -- Water Street Healthcare Partners announced today that Joseph C. Papa has joined its team of senior investment professionals and executives dedicated to growing health care businesses.

Key Points: 
  • CHICAGO, June 14, 2023 /PRNewswire/ -- Water Street Healthcare Partners announced today that Joseph C. Papa has joined its team of senior investment professionals and executives dedicated to growing health care businesses.
  • I'm excited to work with Water Street to build a company that will make a meaningful impact in health care.
  • Working with Mr. Papa, Water Street is in discussions with founders and leadership teams of specialty pharmaceutical businesses that are interested in a partner to advance their goals for growth.
  • In addition to pharmaceutical businesses, Water Street is pursuing investments in companies specializing in life sciences, medical diagnostics and products, and health care services.

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Monday, April 10, 2023
Cocrystal, Nobel Prize, Precigen, Schering-Plough, Warburg Pincus, OPKO Health, CFO, Lomb, COCP, Pharmaceutical industry, Bausch

BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million.

Key Points: 
  • BOTHELL, Wash., April 10, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces the completion of a private placement of 2,030,458 shares of common stock at a price of $1.97 per share for proceeds of $4.0 million.
  • Investors in the private placement were Cocrystal Director and co-founder Phillip Frost, M.D., who serves as Chairman and CEO of OPKO Health, and Fred Hassan who is Chairman of the investment firm Caret Group and Director of the private equity firm Warburg Pincus.
  • Frost has increased his holdings and we welcome Mr. Hassan as a new shareholder,” said James Martin, co-CEO and CFO.
  • The Company also expects to select a lead oral candidate in its norovirus program by mid-2023.

SparingVision appoints Joseph C. Papa as Chairman

Retrieved on: 
Wednesday, April 5, 2023
IPO, Actavis, Pharmaceutical Advertising Advisory Board, Bausch, Retinitis pigmentosa, Hope, Bausch Health, Retina, Cardinal Health, Novartis, Patient, Lomb, NYSE, Pharmaceutical industry, Perrigo

Paris, April 5, 2023 – SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Joseph C. Papa as its independent Chairman.

Key Points: 
  • Paris, April 5, 2023 – SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Joseph C. Papa as its independent Chairman.
  • Papa brings over 30 years of experience in the healthcare sector, having most recently served as Chief Executive Officer and Chairman at Bausch and Lomb Corporation (“Bausch and Lomb”) (NYSE: BLCO) a global eye health company.
  • During his tenure, Papa successfully led the Company's IPO in May 2022 to raise $630 million.
  • Before that, Papa held the role of President and Chief Operating Officer at Watson Pharmaceuticals and worked for 14 years at Novartis Pharmaceuticals in the US and Switzerland.

Rectify Pharmaceuticals Expands Clinical Drug Development Expertise with Board and SAB Appointments

Retrieved on: 
Tuesday, February 14, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Primary biliary cholangitis, Bausch, NASH, United States Air Force Scientific Advisory Board, NDA, University College London, Therapy, PTC, The Washington Campus Board of Directors, Intercept Pharmaceuticals, New York University Stern School of Business, Medication, Pfizer, Drug development, Nightstar, Acquisition, Patient, Business, Lomb, Ophthalmology, University, Biogen, Sequah Medicine Company, Flagship Pioneering, IPO, New York University, PTC Therapeutics, PBC, Intercept, Fatty liver disease, ABC, Massachusetts General Hospital, Pharmaceutical industry, Medical device

“Dr.

Key Points: 
  • “Dr.
  • Ong has a proven track record of building world class companies and a wealth of experience in the development of novel therapies.
  • Dr. Campagna has deep expertise in biliary and liver disease drug development and extensive clinical development experience.
  • He also held leadership roles at Bausch and Lomb and at Pfizer, with more than 20 years’ experience in clinical and drug development.

New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

Retrieved on: 
Tuesday, February 7, 2023
Social Media, Biotechnology, Optical, Managed Care, General Health, Health, Communications, Other Health, Bausch & Lomb, Paratriathlon, Smoking, NYSE, Lomb, AMD, Patient, Surgery, Fear, Risk, Anxiety, Exercise, Love, Social media, Nursing

The campaign, ‘What Sight Inspires You’, will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educational resource designed for people living with AMD, along with educational content on AMD.

Key Points: 
  • The campaign, ‘What Sight Inspires You’, will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educational resource designed for people living with AMD, along with educational content on AMD.
  • The campaign will run on the SightMatters Facebook page throughout the month of February.
  • “For eight years, Bausch + Lomb has supported AMD Awareness Month through a variety of campaigns.
  • “Many AMD patients feel frightened and unsettled when they are diagnosed because of what it can potentially mean for their sight and life long-term,” said Rishi Singh, staff physician and president, Cleveland Clinic Martin Hospitals, Stuart, Fla. “I applaud Bausch + Lomb for demonstrating how AMD patients can continue to live vibrantly through this year’s campaign.